Newamsterdam Pharma Stock Performance
| NAMSW Stock | 12.51 0.24 1.96% |
The company secures a Beta (Market Risk) of -2.59, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning NewAmsterdam Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, NewAmsterdam Pharma is expected to outperform it. NewAmsterdam Pharma right now secures a risk of 5.72%. Please verify NewAmsterdam Pharma sortino ratio, semi variance, as well as the relationship between the Semi Variance and day median price , to decide if NewAmsterdam Pharma will be following its current price movements.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days NewAmsterdam Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, NewAmsterdam Pharma is not utilizing all of its potentials. The newest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return 4.84 | Five Day Return 6.12 | Year To Date Return (9.66) | Ten Year Return 409.8 | All Time Return 409.8 |
Last Split Factor 1:1 | Last Split Date 2022-11-23 |
1 | Acquisition by Smither John W of 10000 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3 | 12/27/2024 |
2 | NewAmsterdam Pharma Reaches New 1-Year High - Whats Next - MarketBeat | 01/08/2025 |
3 | NewAmsterdam Pharma Company N.V. Analysts Recommend This 52-Week High Stocks Now - Insider Monkey | 01/15/2025 |
4 | Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday - AOL | 02/06/2025 |
5 | NewAmsterdam Pharma Given Consensus Rating of Buy by Brokerages - MarketBeat | 02/14/2025 |
6 | NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update | 02/26/2025 |
7 | Newamsterdam Pharma COO Kling sells 2.36 million in stock - Investing.com | 03/19/2025 |
| Begin Period Cash Flow | 340.4 M |
NewAmsterdam |
NewAmsterdam Pharma Relative Risk vs. Return Landscape
If you would invest 1,342 in NewAmsterdam Pharma on December 23, 2024 and sell it today you would lose (91.00) from holding NewAmsterdam Pharma or give up 6.78% of portfolio value over 90 days. NewAmsterdam Pharma is currently producing 0.0452% returns and takes up 5.7191% volatility of returns over 90 trading days. Put another way, 51% of traded stocks are less volatile than NewAmsterdam, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NewAmsterdam Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewAmsterdam Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NewAmsterdam Pharma, and traders can use it to determine the average amount a NewAmsterdam Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0079
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NAMSW |
Estimated Market Risk
| 5.72 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.05 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NewAmsterdam Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NewAmsterdam Pharma by adding NewAmsterdam Pharma to a well-diversified portfolio.
NewAmsterdam Pharma Fundamentals Growth
NewAmsterdam Stock prices reflect investors' perceptions of the future prospects and financial health of NewAmsterdam Pharma, and NewAmsterdam Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NewAmsterdam Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (3.38) % | ||||
| Revenue | 45.56 M | ||||
| Gross Profit | 45.56 M | ||||
| EBITDA | (241.49 M) | ||||
| Net Income | (241.6 M) | ||||
| Total Debt | 448 K | ||||
| Book Value Per Share | 7.01 X | ||||
| Cash Flow From Operations | (158.56 M) | ||||
| Total Asset | 864.62 M | ||||
| Retained Earnings | (558.57 M) | ||||
| Working Capital | 756.5 M | ||||
About NewAmsterdam Pharma Performance
Evaluating NewAmsterdam Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NewAmsterdam Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NewAmsterdam Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.29) | |
| Return On Capital Employed | (0.23) | (0.22) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | (0.32) | (0.30) |
Things to note about NewAmsterdam Pharma performance evaluation
Checking the ongoing alerts about NewAmsterdam Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NewAmsterdam Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NewAmsterdam Pharma had very high historical volatility over the last 90 days | |
| NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 45.56 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 45.56 M. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| NewAmsterdam Pharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Newamsterdam Pharma COO Kling sells 2.36 million in stock - Investing.com |
- Analyzing NewAmsterdam Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NewAmsterdam Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NewAmsterdam Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NewAmsterdam Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NewAmsterdam Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NewAmsterdam Pharma's stock. These opinions can provide insight into NewAmsterdam Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.